Psychiatry Research: Neuroimaging
Volume 156, Issue 1 , Pages 75-82 , 15 October 2007

Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with 99mTc TRODAT-1 imaging

  • Chin-Bin Yeh

      Affiliations

    • Department of Psychiatry, Tri-Service General Hospital, National Defense Medical School, Taipei, Taiwan, ROC
    • Graduate Institute of Medical Sciences, Tri-Service General Hospital, National Defense Medical School, Taipei, Taiwan, ROC
    • ,
  • Chung-Shian Lee

      Affiliations

    • Department of Nuclear Medicine, Chi-Mei General Hospital, Tainan, Taiwan, ROC
    • ,
  • Kuo-Hsing Ma

      Affiliations

    • Department of Anatomy and Biology, National Defense Medical School, Taipei, Taiwan, ROC
    • ,
  • Meei-Shyuan Lee

      Affiliations

    • School of Public Health, National Defense Medical School, Taipei, Taiwan, ROC
    • ,
  • Chia-Jung Chang

      Affiliations

    • School of Public Health, National Defense Medical School, Taipei, Taiwan, ROC
    • ,
  • Wen-Sheng Huang

      Affiliations

    • Department of Nuclear Medicine, Tri-Service General Hospital, National Defense Medical School, Taipei, Taiwan, ROC
    • Corresponding Author InformationCorresponding author. Tel.: +886 2 8792 7374; fax: +886 2 8792 7217.

Received 15 July 2006 ,Revised 29 December 2006 ,Accepted 14 January 2007.

References 

  1. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain. 2005;128:2760–2762
  2. Albin RL. Neurobiology of basal ganglia and Tourette syndrome: striatal and dopamine function. Advances in Neurology. 2006;99:99–106
  3. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 2003;61:310–315
  4. Berridge KC, Aldridge JW, Houchard KR, Zhuang X. Sequential super-stereotypy of an instinctive fixed action pattern in hyper-dopaminergic mutant mice: a model of obsessive compulsive disorder and Tourette's. BMC Biology. 2005;3:4
  5. Bloch MH, Leckman JF, Zhu H, Peterson BS. Caudate volumes in childhood predict symptom severity in adults with Tourette syndrome. Neurology. 2005;65:1253–1258
  6. Bloch MH, Peterson BS, Scahill L, Otka J, Katsovich L, Zhang H, et al. Adulthood outcome of tic and obsessive–compulsive symptom severity in children with Tourette syndrome. Archives of Pediatrics and Adolescent Medicine. 2006;160:65–69
  7. Breit S, Reimold M, Reischl G, Klockgether T, Wullner U. [11C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. Journal of Neural Transmission. 2005;113:187–193
  8. Chen R, Han DD, Gu HH. A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. Journal of Neurochemistry. 2005;94:352–359
  9. Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder. Psychiatry Research: Neuroimaging. 2004;130:85–95
  10. Cohen DJ, Shaywitz BA, Young JG, Carbonari CM, Nathanson JA, Lieberman D, et al. Central biogenic amine metabolism in children with the syndrome of chronic multiple tics of Gilles de la Tourette: norepinephrine, serotonin, and dopamine. Journal of the American Academy of Child Psychiatry. 1979;18:320–341
  11. Dresel SH, Kung MP, Plossl K, Meegalla SK, Kung HF. Pharmacological effects of dopaminergic drugs on in vivo binding of [99mTc]TRODAT-1 to the central dopamine transporters in rats. European Journal of Nuclear Medicine. 1998;25:31–39
  12. Edwards MJ, Dale RC, Church AJ, Trikouli E, Quinn NP, Lees AJ, et al. Adult-onset tic disorder, motor stereotypies, and behavioural disturbance associated with antibasal ganglia antibodies. Movement Disorders. 2004;19:1190–1196
  13. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Dhawan V, Budman C, et al. The metabolic anatomy of Tourette's syndrome. Neurology. 1997;48:927–934
  14. Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascualvaca D, Cohen RM. High presynaptic dopaminergic activity in children with Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:86–94
  15. Federici M, Geracitano R, Bernardi G, Mercuri NB. Actions of methylphenidate on dopaminergic neurons of the ventral midbrain. Biological Psychiatry. 2005;57:361–365
  16. Fukui R, Svenningsson P, Matsuishi T, Higashi H, Nairn AC, Greengard P, et al. Effect of methylphenidate on dopamine/DARPP signalling in adult, but not young, mice. Journal of Neurochemistry. 2003;87:1391–1401
  17. Gainetdinov RR, Jones SR, Fumagalli F, Wightman RM, Caron MG. Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis. Brain Research Reviews. 1998;26:148–153
  18. Golden, G.S., 1988. The relationship between stimulant medication and tics. Pediatric Annals 17, 405–406, 408.
  19. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41:1–24
  20. Heinz A, Knable MB, Wolf SS, Jones DW, Gorey JG, Hyde TM, et al. Tourette's syndrome: [I-123]beta-CIT SPECT correlates of vocal tic severity. Neurology. 1998;51:1069–1074
  21. Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson's disease with [99mTc]TRODAT-1 imaging. Journal of Nuclear Medicine. 2001;42:1303–1308
  22. Huang WS, Lee MS, Lin JC, Chen CY, Yang YW, Lin SZ, et al. Usefulness of brain [99mTc]TRODAT-1 SPET for the evaluation of Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:155–161
  23. Hyde TM, Stacey ME, Coppola R, Handel SF, Rickler KC, Weinberger DR. Cerebral morphometric abnormalities in Tourette's syndrome: a quantitative MRI study of monozygotic twins. Neurology. 1995;45:1176–1182
  24. Krause KH, Dresel S, Krause J, Kung HF, Tatsch K, Lochmuller H. Elevated striatal dopamine transporter in a drug naive patient with Tourette syndrome and attention deficit/ hyperactivity disorder: positive effect of methylphenidate. Journal of Neurology. 2002;249:1116–1118
  25. Krause J, la Fougere C, Krause KH, Ackenheil M, Dresel SH. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. European Archives of Psychiatry and Clinical Neuroscience. 2005;255:428–431
  26. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plössl K, Lee HK. Imaging of dopamine transporters in humans with [99mTc]TRODAT-1. European Journal of Nuclear Medicine. 1996;23:1527–1530
  27. Kung MP, Stevenson DA, Plössl K, Meegalla SK, Beckwith A, Essman WD, et al. [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent. European Journal of Nuclear Medicine. 1997;24:372–380
  28. Kushner SA, McElgin WT, Kung MP, Mozley PD, Plössl K, Meegalla SK, et al. Kinetic modeling of [99mTc]TRODAT-1: a dopamine transporter imaging agent. Journal of Nuclear Medicine. 1999;40:150–158
  29. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry. 1989;28:566–573
  30. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Seibyl JP, et al. [123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. American Journal of Psychiatry. 1995;152:1359–1361
  31. Meyer P, Bohnen NI, Minoshima S, Koeppe RA, Wernette K, Kilbourn MR, et al. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology. 1999;53:371–374
  32. Mozley PD, Stubbs JB, Plössl K, Dresel SH, Barraclough ED, Alavi A, et al. Biodistribution and dosimetry of TRODAT-1: a technetium-99m tropane for imaging dopamine transporters. Journal of Nuclear Medicine. 1998;39:2069–2076
  33. Mozley PD, Schneider JS, Acton PD, Plössl K, Stern MB, Siderowf A, et al. Binding of [99mTc] TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. Journal of Nuclear Medicine. 2000;41:584–589
  34. Muller-Vahl KR, Berding G, Brucke T, Kolbe H, Meyer GJ, Hundeshagen H, et al. Dopamine transporter binding in Gilles de la Tourette syndrome. Journal of Neurology. 2000;247:514–520
  35. Nikolaus S, Wirrwar A, Antke C, Arkian S, Schramm N, Muller HW, et al. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT. European Journal of Nuclear Medicine and Molecular Imaging. 2005;32:308–313
  36. Nomura Y, Segawa M. Neurology of Tourette's syndrome (TS) as a developmental dopamine disorder: a hypothesis. Brain & Development. 2003;25:37–42
  37. Peterson BS, Thomas P, Kane MJ, Scahill L, Zhang H, Bronen R, et al. Basal ganglia volumes in patients with Gilles de la Tourette syndrome. Archives of General Psychiatry. 2003;60:415–424
  38. Serra-Mestres J, Ring HA, Costa DC, Gacinovic S, Walker Z, Lees AJ, et al. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatrica Scandinavica. 2004;109:140–146
  39. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry. 1989;46:722–730
  40. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry. 1998;59(20):22–33
  41. Singer HS, Hahn IH, Moran TH. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Annals of Neurology. 1991;30:558–562
  42. Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. American Journal of Psychiatry. 2002;159:1329–1336
  43. Stamenkovic M, Schindler SD, Asenbaum S, Neumeister A, Willeit M, Willinger U, et al. No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: a [123I]beta-CIT SPECT study. European Neuropsychopharmacology. 2001;11:69–74
  44. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry. 1998;155:1325–1331
  45. Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. Journal of Attention Disorders. 2002;6:31–43
  46. Wolf SS, Jones DW, Knable MB, Gorey JG, Lee KS, Hyde TM, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 1996;273:1225–1227
  47. Wong DF, Singer HS, Brandt J, Shaya E, Chen C, Brown J, et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. Journal of Nuclear Medicine. 1997;38:1243–1247

PII: S0925-4927(07)00017-0

doi: 10.1016/j.pscychresns.2007.01.003

Psychiatry Research: Neuroimaging
Volume 156, Issue 1 , Pages 75-82 , 15 October 2007

Article Tools

* Image Usage & Resolution